✦ LIBER ✦

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

✍ Scribed by Reck, Martin; Kaiser, Rolf; Mellemgaard, Anders; Douillard, Jean-Yves; Orlov, Sergey; Krzakowski, Maciej; von Pawel, Joachim; Gottfried, Maya; Bondarenko, Igor; Liao, Meilin; Gann, Claudia-Nanette; Barrueco, José; Gaschler-Markefski, Birgit; Novello, Silvia

Book ID: 121524875
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 382 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70586-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Vandetanib plus docetaxel versus docetax

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

✍ Roy S Herbst; Yan Sun; Wilfried EE Eberhardt; Paul Germonpré; Nagahiro Saijo; Ca 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 327 KB

Randomized, Placebo-Controlled Phase II

Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Non Small-Cell Lung Cancer

✍ Heymach, J. V.; Johnson, B. E.; Prager, D.; Csada, E.; Roubec, J.; Pesek, M.; Sp 📂 Article 📅 2007 🏛 American Society of Clinical Oncology 🌐 English ⚖ 209 KB

Gefitinib versus docetaxel in previously

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

✍ Edward S Kim; Vera Hirsh; Tony Mok; Mark A Socinski; Radj Gervais; Yi-Long Wu; L 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 243 KB

Ramucirumab plus docetaxel versus placeb

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

✍ Garon, Edward B (author);Ciuleanu, Tudor-Eliade (author);Arrieta, Oscar (author) 📂 Article 📅 2014 🏛 Elsevier BV 🌐 English ⚖ 389 KB

Docetaxel plus trans-tracheal injection

Docetaxel plus trans-tracheal injection of adenoviral-mediated p53 versus docetaxel alone in patients with previously treated non-small-cell lung cancer

✍ Ning, X; Sun, Z; Wang, Y; Zhou, J; Chen, S; Chen, D; Zhang, H 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 273 KB

9001 Vandetanib plus docetaxel versus do

9001 Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial

✍ Eberhardt, W.E.E.; Johnson, B.E.; Sun, Y.; Germonpré, P.; Saijo, N.; Zhou, C.; W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB